New drug combo targets Hard-to-Treat bladder cancer
NCT ID NCT03744793
First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times
Summary
This study tests a combination of two drugs, pemetrexed and avelumab, in people with a specific type of advanced bladder cancer that lacks a protein called MTAP. The goal is to see if this treatment can shrink or control the cancer. About 18 participants who have already tried chemotherapy will receive the drug combo to measure response and survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFILTRATING BLADDER UROTHELIAL CARCINOMA SARCOMATOID VARIANT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Targeted drug hunts down cancer cells in advanced bladder cancer trial
- New drug option for Hard-to-Treat cancers with FGFR3 mutations
- New bladder cancer drug aims to fight tumors without harming nerves
- New hope for advanced bladder cancer? bevacizumab combo tested
- New cocktail of drugs takes on Hard-to-Treat bladder cancer
- New imaging tracer could spot hidden cancers